What is ARCT stock price today?

ARCT (Arcturus Therapeutics Holdings Inc) stock is trading at $6.39 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ARCT stock going up or down today?

ARCT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ARCT stock now?

The decision to buy ARCT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ARCT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ARCT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ARCT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ARCT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ARCT's P/E ratio?

P/E ratio data for ARCT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ARCT's market cap?

ARCT (Arcturus Therapeutics Holdings Inc) has a market capitalization of $0.18 billion, making it a small-cap stock.

What is ARCT's price to book ratio?

ARCT trades at a price-to-book (P/B) ratio of 0.88, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ARCT pay dividends?

ARCT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ARCT's dividend yield?

ARCT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ARCT stock a good long-term investment?

ARCT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ARCT's revenue growth rate?

ARCT has shown revenue growth of -0.7% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

ARCT is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in ARCT?

Key risks for ARCT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ARCT compare to its competitors?

Compare ARCT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ARCT's performance and positioning.

What is ARCT's stock price target for 2026?

Our AI model provides price targets for ARCT based on fundamental analysis: Bull case $8.31 (+30%), Base case $7.35 (+15%), Bear case $5.75 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ARCT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ARCT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ARCT's next earnings report?

ARCT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ARCT - Arcturus Therapeutics Holdings Inc

NYSE * Health Care * Biotechnology

$6.39

$-0.24 (-3.62%)

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Key Statistics

Market Cap

$181.62M

P/B Ratio

0.88

EPS

$-2.31

Revenue Growth

-0.7%

Profit Margin

-0.8%

Employees

106

How ARCT Compares to Peers

ARCT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ARCT(This stock)	$181.62M	N/A	-1%	-0.8%	-
AMGNAmgen Inc	$197.43B	25.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$180.27B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$118.39B	30.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.02B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.19B	21.1	-0%	0.1%	vs BIIB

Arcturus Therapeutics Holdings Inc Company Information

Headquarters: California; U.S.A
Website: arcturusrx.com
Sector: Health Care
Industry: Biotechnology

ARCT - Arcturus Therapeutics Holdings Inc

About Arcturus Therapeutics Holdings Inc

ARCT Key Statistics

How ARCT Compares to Peers

Arcturus Therapeutics Holdings Inc Company Information

ARCT Lician Score

ARCT Financial Snowflake

Upcoming Events for ARCT